CHS-0214 (etanercept biosimilar) / Coherus Biosci  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CHS-0214 (etanercept biosimilar) / Coherus Biosci
NCT02134210 / 2014-000444-14: Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

Checkmark For psoriasis
Nov 2015 - Nov 2015: For psoriasis
Completed
3
521
Canada, US, Europe, RoW
Etanercept, Enbrel, European Enbrel, CHS-0214
Coherus Biosciences, Inc., Shire
Plaque Psoriasis
07/15
05/16
CHS-0214-02, NCT02115750 / 2014-000443-33: Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

Checkmark Completion of dosing in P3 trial
Jun 2016 - Jun 2016: Completion of dosing in P3 trial
Checkmark Comparison of CHS-0214 to etanercept in RA at EULAR 2016
Jun 2016 - Jun 2016: Comparison of CHS-0214 to etanercept in RA at EULAR 2016
Checkmark RAPSODY
More
Completed
3
647
Japan, US, Europe, RoW
Etanercept, Enbrel, European Enbrel, CHS-0214
Coherus Biosciences, Inc., Daiichi Sankyo Co., Ltd.
Rheumatoid Arthritis
10/15
05/16
CHS-0214-05, NCT02486939 / 2015-000665-30: A Long Term Safety Extension Study

Completed
3
359
Japan
CHS-0214
Coherus Biosciences, Inc., Daiichi Sankyo Co., Ltd., Shire
Rheumatoid Arthritis, Plaque Psoriasis
09/17
10/17

Download Options